Press release
Deadline on June 11, 2021, coming up in Lawsuit for Investors in FibroGen, Inc. (NASDAQ: FGEN)
A Deadline is coming up on June 11, 2021 in the lawsuit for certain investors in FibroGen, Inc. (NASDAQ: FGEN).
Investors who purchased shares of FibroGen, Inc. (NASDAQ: FGEN) have certain options and there are strict and short deadlines running. Deadline: June 11, 2021. NASDAQ: FGEN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common shares between November 8, 2019 and April 6, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 8, 2019 and April 6, 2021, the Defendants failed to disclose to investors that the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of CKD included post-hoc changes to the stratification factors, that FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals, that, based on these analyses, the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa, that, as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA, and that, as a result of the foregoing, Defendants' statements about the Company's business, operations and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of FibroGen, Inc. (NASDAQ: FGEN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on June 11, 2021, coming up in Lawsuit for Investors in FibroGen, Inc. (NASDAQ: FGEN) here
News-ID: 2296978 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for FibroGen
Investigation for Investors in shares of FibroGen, Inc. (NASDAQ: FGEN) over pote …
An investigation was announced for current long-term investors in shares of FibroGen, Inc. (NASDAQ: FGEN over potential breaches of fiduciary duties by certain directors at FibroGen, Inc.
Investors who purchased shares of FibroGen, Inc. (NASDAQ: FGEN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain FibroGen, Inc. directors breached their fiduciary duties and caused damage…
FibroGen, Inc. (NASDAQ: FGEN) Long Term Investor Notice: Lawsuit filed against c …
An investor in shares of FibroGen, Inc. (NASDAQ: FGEN) filed a lawsuit against certain directors of FibroGen, Inc over alleged breaches of fiduciary duties.
Investors who are current long term investors in FibroGen, Inc. (NASDAQ: FGEN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff alleges that certain directors and officers of Fibrogen breached their fiduciary duties in connection with…
Neurotrophins Market Report: Trends, Forecast and Competitive Analysis By 2028 | …
The business models, main strategies, and respective market shares of some of the most notable companies in the Neurotrophins market are all examined in depth in this report. The comprehensive analysis includes market statistics in terms of revenues, segment-by-segment data, region-by-region data, and country-by-country data, as well as an in-depth commentary on the key affecting variables. This research is one of the most thorough studies available, capturing all aspects of…
Hyperconverged Infrastructure Market In Depth Analysis 2021 To 2027- Johnson＆J …
Complete study of the global Neurotrophins market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Neurotrophins industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate…
Investigation announced for Investors in shares of FibroGen, Inc. (NASDAQ: FGEN)
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of FibroGen, Inc..
Investors who are current long term investors in FibroGen, Inc. (NASDAQ: FGEN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: FGEN stocks follows a lawsuit filed against FibroGen, Inc. over…
Lawsuit filed for Investors in shares of FibroGen, Inc. (NASDAQ: FGEN)
An investor, who purchased shares of FibroGen, Inc. (NASDAQ: FGEN), filed a lawsuit over alleged violations of Federal Securities Laws by FibroGen, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of FibroGen, Inc. (NASDAQ: FGEN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 11, 2021. NASDAQ: FGEN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
